透析相关性低血压的8大预警信号

2018-11-08 佚名 沈阳军区总医院净化中心

透析相关性低血压指平均动脉压比透析前下降30 mmHg以上,收缩压降至90 mmHg以下。是透析患者常见的并发症之一,发生率为25%-50%,多出现于透析的初始或后1-2小时内,临床上可表现出一系列的前驱症状。

透析相关性低血压指平均动脉压比透析前下降30 mmHg以上,收缩压降至90 mmHg以下。是透析患者常见的并发症之一,发生率为25%-50%,多出现于透析的初始或后1-2小时内,临床上可表现出一系列的前驱症状。

1. 出汗伴恶心呕吐

多由于超滤量过多或超滤速度过快引起血容量下降所致。患者表现为焦虑、出汗,自诉无力,胸闷不适、烦热,应警惕低血压的发生。如不及时处理随即患者大汗淋漓,可伴有恶心呕吐等即已发生低血压。

2. 肌肉痉挛

透析发生率为10%-15%。由于超滤过多过快,循环血量减少和肌肉脱水过多有关。多发生于透析中或透析后数小时内,表现为:局部肌肉强直性收缩(俗称抽筋),下肢肌肉或腹部肌肉痉挛,疼痛剧烈。肌肉痉挛发生的同时或随后即有血压下降,一般可持续数分钟。

3. 口渴,声音嘶哑

多发生于患者体重控制不理想,透析间期体重增长过多的患者。特别是上机前短时间内饮用大量的水,当血管内的水分被脱出,血管外组织间隙的水不能及时转移到血管内,导致超滤量大于组织液的回流量,患者自感极度口渴、烦热、说话声音沙哑,警惕血压即将下降或已开始下降。

4. 眼球干涩,凹陷

常发生于初始阶段透析的年轻患者。在没有掌握好干体重的情况下,超滤率设定过大,再出现负超值时,机体各方面处于代偿阶段时,眼球会出现干涩不适、凹陷伴口渴,应警惕低血压即将发生。

5. 腹痛,便意感

多发生于贫血、糖尿病、基础血压低、血容量不足的患者。患者自诉腹部疼痛、有便意,似伤食腹泻感,症状反应急,患者往往要求立即停机排便,但多无大便排出。当血液回输入体内,症状随即减弱或消失。重新上机要及时调整透析参数,防止低血压的发生。

6. 打哈欠

多发生于透析3-4小时内,由于超滤量过多,血液循环量减少,供应于脑组织的血液量相对不足,患者往往频频打哈欠。而频繁打哈欠时,监测血压并无大的变化,常常瞬间低血压即发生,且程度严重,患者常伴呕吐,大汗,甚至出现一过性意识丧失,应予以高度警惕。

7. 头晕、头痛

多发生于老年体弱或糖尿病患者。患者心脏代偿不全,血浆再充盈不足,静脉容量扩张,动脉张力降低等。当将体内血液的一部分引出进行体外循环时,则造成脑缺血缺氧引起头晕、头痛。随即可能会发生低血压。


另外糖尿病患者为防止透析中低血糖的发生,透析中过多过快的进食食物,使部血管扩张,血液分流,引起短暂性的供血不足,患者往往首先表现为头晕、头痛,之后应警惕低血压的发生。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1009624, encodeId=bf0f1009624d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/b7a64c53cc944fed9f929b23bad22004/7f2fd5fb135d454e823fcf64fa76bd8f.jpg, createdBy=b07a5542322, createdName=nahsey, createdTime=Fri Aug 20 08:07:46 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837595, encodeId=ac0a183e59515, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Aug 15 15:09:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367378, encodeId=dfe8136e37824, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 10 10:09:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351967, encodeId=298c35196eb4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Nov 08 19:41:41 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2021-08-20 nahsey

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1009624, encodeId=bf0f1009624d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/b7a64c53cc944fed9f929b23bad22004/7f2fd5fb135d454e823fcf64fa76bd8f.jpg, createdBy=b07a5542322, createdName=nahsey, createdTime=Fri Aug 20 08:07:46 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837595, encodeId=ac0a183e59515, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Aug 15 15:09:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367378, encodeId=dfe8136e37824, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 10 10:09:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351967, encodeId=298c35196eb4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Nov 08 19:41:41 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1009624, encodeId=bf0f1009624d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/b7a64c53cc944fed9f929b23bad22004/7f2fd5fb135d454e823fcf64fa76bd8f.jpg, createdBy=b07a5542322, createdName=nahsey, createdTime=Fri Aug 20 08:07:46 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837595, encodeId=ac0a183e59515, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Aug 15 15:09:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367378, encodeId=dfe8136e37824, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 10 10:09:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351967, encodeId=298c35196eb4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Nov 08 19:41:41 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1009624, encodeId=bf0f1009624d5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/b7a64c53cc944fed9f929b23bad22004/7f2fd5fb135d454e823fcf64fa76bd8f.jpg, createdBy=b07a5542322, createdName=nahsey, createdTime=Fri Aug 20 08:07:46 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837595, encodeId=ac0a183e59515, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Aug 15 15:09:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367378, encodeId=dfe8136e37824, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 10 10:09:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351967, encodeId=298c35196eb4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Nov 08 19:41:41 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2018-11-08 医者仁心5538

    学习了

    0

相关资讯

丙肝抗病毒治疗与血液透析,如何取得双赢的局面?

治疗慢性丙型病毒性肝炎(CHC)合并肾功能衰竭血液透析的患者,我们需要既不影响肾功,又不被血液透析影响疗效的理想药物。

人造肾脏即将投入实验 未来有望取代透析和移植技术

据英国《每日邮报》报道,“人造肾脏”预计将在今年晚些时候开始进行首次人体试验,一旦成功,将在几年内投入使用,取代透析和移植技术,挽救人们的生命。

J Am Soc Nephrol:年龄和肾功能不同的晚期CKD老年患者,透析vs药物对生存期的影响

2018年8月,发表在《J Am Soc Nephrol》的一项由美国学者进行的分析,在不同年龄和肾功能的晚期CKD老年患者中,考察了透析vs药物管理与生存期之间的相关性

J Thromb Haemost:透析患者因出血、心肌梗死和卒中导致的死亡率分析

由此可见,与一般人群相比,透析患者因出血和动脉血栓形成而死亡的风险大大增加。临床医生应该意识到这些疾病导致的死亡风险增加。

维持性血透患者10大常规检查,你都知道吗?

部分血液透析患者在规律治疗情况明显好转后,即认为只要按时透析就行,没必要做一些化验检查。而实际上,却犯了一个很大的错误,因为透析并不能解决疾病本身带来的所有问题,有些问题必须应用药物去干预,而且应定期调整药方案。

Circulation:阿哌沙班可降低晚期肾病/房颤患者的大出血、血栓栓塞和死亡风险

进行透析的晚期肾病(ESKD)患者被排除在房颤(AF)进行直接口服抗凝剂的临床试验外。近期的数据引起了人们对达比加群和利伐沙班安全性的担忧,但阿哌沙班尚未有评估,虽然目前的标签支持其应用于该人群。现研究人员尝试确定阿哌沙班在依赖透析的ESKD和AF患者中的应用模式及其相关预后。研究人员对包括美国肾脏数据系统的医疗保险受益人进行回顾性队列研究。筛选开始进行口服抗凝剂治疗的依赖透析的ESKD和AF患者